Triheptanoin in GLUT1DS
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
PRE
P1
P2
P3
Edit
Updated: 05/17/2019
Pipeline Type
Dietary Supplements
Phase Of Development
Phase 2
Sponsors and Collaborators
Ultragenyx;
Adrian Lacy, Cook Children's
Mechanism of Action
Mechanism Description
triglyceride; three seven-carbon fatty acids; provide anaplerotic substrates for the TCA cycle
Populations Tested In
Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Other Resources
Special FDA Designation
Nonprofit or Government Support
N/A
Nonprofit or Government Support Description
N/A
Previous Presentations
Presented at meetings (latest date) (Pipeline, AEDD; AES, Eilat, etc)
N/A
Location of Clinical Trials
Cook Children's Medical
Fort Worth, TX
Clinical Trial link